CFB
VIVO

Cullen/Frost Bankers’s Meridian Bioscience Inc VIVO Stock Holding History

Cullen/Frost Bankers’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-784
Closed -$15K – 1365
2021
Q3 		$15K Hold
784
– – ﹤0.01% 1024
2021
Q2 		$17K Buy
+784
New +$16.6K ﹤0.01% 1017

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Cullen/Frost Bankers's VIVO Position: Q4 2021 in Review

Cullen/Frost Bankers sold out of Meridian Bioscience Inc (VIVO) in Q4 2021, closing a stake of 784 shares — an estimated $15K sold.

Cullen/Frost Bankers first reported a position in VIVO in Q2 2021 and held it in 2 quarters. The position peaked at $17K in Q2 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2021.

  • Cullen/Frost Bankers reported no remaining Meridian Bioscience Inc position as of Q4 2021 after selling out during the quarter.
  • Cullen/Frost Bankers sold 784 Meridian Bioscience Inc shares in Q4 2021, an estimated $15K.
  • Cullen/Frost Bankers first reported a position in Meridian Bioscience Inc in Q2 2021 and held it in 2 quarters.
  • Cullen/Frost Bankers's Meridian Bioscience Inc position peaked at $17K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2021.

Based on Cullen/Frost Bankers's 13F filing for Q4 2021, filed 7 Feb 2022.